Story perspectives

Eli Lilly Seeks Approval for Weight Loss Breakthrough

8/27/2025

23 5

Summary

Story summary

Eli Lilly plans to seek global regulatory approval for its oral GLP-1 medication, orforglipron, following successful trials.
Participants experienced an average weight loss of 22.9 pounds and a 1.8% reduction in A1C levels over 72 weeks.
Side effects were mild and comparable to those of injectable forms.
Lilly intends to mass-produce the medication and investigate further applications.
The company aims to publish trial results in a peer-reviewed journal.

1 of 1

Story summary

Eli Lilly plans to seek global regulatory approval for its oral GLP-1 medication, orforglipron, following successful trials.
Participants experienced an average weight loss of 22.9 pounds and a 1.8% reduction in A1C levels over 72 weeks.
Side effects were mild and comparable to those of injectable forms.
Lilly intends to mass-produce the medication and investigate further applications.
The company aims to publish trial results in a peer-reviewed journal.